申请人:ORION CORPORATION
公开号:US20160130254A1
公开(公告)日:2016-05-12
Compounds of formula (I)
wherein R
1
to R
8
, A, B, Z
1
, and Z
2
are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17α-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
公式(I)化合物的结构式中,其中R1至R8,A,B,Z1和Z2如权利要求所定义,并且其药学上可接受的盐和酯被揭示。公式(I)化合物具有作为雄激素受体拮抗剂(抑制剂)和/或细胞色素P450单加氧酶17α-羟化酶/17,20-裂解酶(CYP17)抑制剂的效用。这些化合物在治疗癌症,特别是前列腺癌和其他需要雄激素拮抗剂的疾病和病情中作为药物是有用的。